Study of setidegrasib with chemo for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that has spread to other parts of the body (metastatic) and it must have a specific gene change called KRAS G12D.
- You must not be able to have surgery or radiation to cure the cancer.
- You need to provide a tissue sample from your tumor before starting the trial.
- You must be well enough to do daily activities with little or no help (ECOG score of 0 or 1).
- Your liver, kidneys, and bone marrow function must be within certain limits, checked by blood tests within 7 days before starting treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests three new targeted drug combinations for pancreatic cancer that has a specific genetic change (KRAS G12D). They are comparing the study drug alone versus combining it with other investigational drugs to see which works better.
This trial tests a new medicine (DN022150) combined with standard chemotherapy as a first treatment for advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The combination may help shrink or slow the cancer better than chemotherapy alone.
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
This trial tests whether adding a targeted drug called panitumumab to standard chemotherapy can help people with a certain type of pancreatic cancer that has spread. It is for patients whose tumors do not have a KRAS mutation and who have already had one line of chemotherapy.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.